Xenograft Model Antitumor Assays

"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Descriptor ID	D023041
MeSH Number(s)	E05.337.550.200.900 E05.624.850
Concept/Terms	Xenograft Model Antitumor Assays Xenograft Model Antitumor Assays Tumor Xenograft Assay Xenograft Antitumor Assays Antitumor Assay, Xenograft Antitumor Assays, Xenograft Assay, Xenograft Antitumor Assays, Xenograft Antitumor Xenograft Antitumor Assay Antitumor Assays, Xenograft Model

Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]
Xenograft Model Antitumor Assays [E05.337.550.200.900]
Neoplasm Transplantation [E05.624]
Xenograft Model Antitumor Assays [E05.624.850]

Below are MeSH descriptors whose meaning is related to "Xenograft Model Antitumor Assays".

Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".

Xenograft Model Antitumor Assays
Subrenal Capsule Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.

Bar chart showing 254 publications over 23 distinct years, with a maximum of 20 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	2	3
2004	0	1	1
2005	0	4	4
2006	0	6	6
2007	0	2	2
2008	1	12	13
2009	1	9	10
2010	1	14	15
2011	2	17	19
2012	1	11	12
2013	0	19	19
2014	0	12	12
2015	1	19	20
2016	3	13	16
2017	0	19	19
2018	0	9	9
2019	1	16	17
2020	1	15	16
2021	1	8	9
2023	0	1	1
2024	1	13	14
2025	0	14	14
2026	0	3	3

Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.

Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 04; 25(5):685-700.

View in: PubMed
Ahmad M, Alvi SS, Ahsan H, Perez C, Massey A, Kashyap VK, Chauhan N, Anning E, Tripathi MK, Kim DJ, Sahoo N, Oraby T, Yallapu MM, Khan MM, Sebastian MM, Chauhan SC, Hafeez BB. Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.

View in: PubMed
Holliday H, Khan A, Ehteda A, Nguyen H, Ross SE, Jayatilleke N, Gopalakrishnan A, Wang E, Sanguino YC, Kavanagh D, Guo X, Liu J, Lawrence D, Sun CX, Lehmann R, Ip CK, Lee A, Rangel-Sanchez L, Li W, Salomon R, Firestein R, Weatheritt RJ, Valdes-Mora F, Dinger ME, Phoenix TN, Mayoh C, Rayner BS, Tsoli M, Ziegler DS. Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma. Sci Transl Med. 2026 Jan 14; 18(832):eadr1557.

View in: PubMed
Nara A, Shimada S, Akiyama Y, Hatano M, Chino Y, Miyazawa S, Tamura H, Asano D, Ishikawa Y, Ueda H, Watanabe S, Katsuta E, Akahoshi K, Ohashi K, Tanabe M, Ban D, Tanaka S. Targeting SPP1-CD44-Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis. Cancer Sci. 2026 Mar; 117(3):670-682.

View in: PubMed
Chen Q, Dorji JP, Perera SG, Li P, Aijaz F, Ihuoma LC, Matsui H, Awah CU. In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy. BMC Cancer. 2025 Dec 10; 26(1):68.

View in: PubMed
Singh A, Natu A, Anthony F, Muthu H, Khade B, Smoot DT, Ashktorab H, Gupta S. The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells. Clin Epigenetics. 2025 Oct 08; 17(1):168.

View in: PubMed
Xiao S, Peng Y, Peng L, Xie X, Qin J, Ma H, Kang X, Bing C, Huang B, Liang K, Zhao Y, Rong X, Feng X, Fan X, Ashktorab H, Zhang Z, Jin Z, Zhang X. The novel protein SEMA3C-319aa triggers glutathione metabolism-dependent ferroptosis in gastric cancer. Oncogene. 2025 Oct; 44(39):3679-3693.

View in: PubMed
Aare M, Padakanti SC, Singh M. In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts. AAPS PharmSciTech. 2025 Sep 11; 26(7):227.

View in: PubMed
Aare M, Lazarte JMS, Muthu M, Rishi AK, Singh M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug Deliv Transl Res. 2026 Feb; 16(2):693-710.

View in: PubMed
Daniels MH, Castro J, Lee YT, Gotur D, Knockenhauer KE, Grigoriu S, Lockbaum GJ, Cheong JE, Lu C, Brennan D, Buker SM, Liu J, Yao S, Sparling BA, Sickmier EA, Ribich S, Blakemore SJ, Silver SJ, Boriack-Sjodin PA, Duncan KW, Copeland RA. Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9. J Med Chem. 2025 May 08; 68(9):9537-9554.

View in: PubMed

People

Explore

Similar Concepts

Top Journals